Charles River launches initiative to reduce animal testing
Charles River Laboratories International has launched its Alternative Methods Advancement Project (AMAP), an initiative focused on developing alternatives to reduce animal testing.
The company has invested $200 million over the past four years to reduce the use of animal testing and has a five-year goal of investing an additional $300 million.
AMAP initiatives include research projects confirming the safety and efficacy of alternatives – ensuring patient safety remains the priority. The recent launch of Endosafe Trillium, the company’s first rapid animal-free bacterial endotoxin test, offers a path to reducing reliance on horseshoe crab blood.
As part of the strategy, Charles River plans to partner with companies to co-develop solutions and continue to identify technologies to enhance client offerings.
Previous collaborative efforts include the launch of Logica – the AI-solution for candidate nomination – with Valo, study validation of next-generation sequencing in viral safety assays with PathoQuest, and ongoing advancements in digital pathology with Deciphex.
“Advances in science and technology have brought our industry to an inflection point. Alternatives are the path to the next frontier of drug development, allowing us to responsibly drive progress for the patients and animals that depend on our work,” said James Foster, Chairman, President and Chief Executive Officer of Charles River.
Diana Spencer, Senior Digital Content Editor, DDW
